PETMED EXPRESS INC
PETSNASDAQTrading Snapshot
- Day Range
- $0.85 โ $0.87
- 52-Week Range
- $0.85 โ $4.10
- Volume (shares)
- 115,750
- Avg Volume (shares)
- โ
- Shares Outstanding
- 21.7M
- Next Earnings
- 2027-02-04
Fundamentals Snapshot
- Annual Revenue
- $179M
- Last Q Revenue
- $36M
- P/E Ratio
- โ
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-1.39
- Dividend Yield
- 0.14%
- Dilution (1yr)
- +0.3%
PETMED EXPRESS INC
PETSAbout PETMED EXPRESS INC
PetMed Express, Inc., through its various subsidiaries, operates as a prominent pet pharmacy across the United States. The company provides a comprehensive range of both prescribed and over-the-counter animal medications, health-related items, and other essential supplies for canines, felines, and equines. Their non-prescription offerings include products for flea and tick prevention, joint and bone care, vitamins, treats, nutritional supplements, hygiene essentials, and general pet supplies. For prescription needs, they supply heartworm and flea/tick preventatives, alongside medications for conditions such as arthritis, dermatitis, thyroid imbalances, diabetes, pain relief, and cardiovascular issues, often providing generic alternatives. Beyond pharmaceuticals, the company also retails pet food, bedding, crates, stairs, and various other accessories. PetMed Express engages with its clientele through multiple distribution channels: its official website, a dedicated mobile application, a telephone contact center, direct mail campaigns (like brochures and postcards), and television advertisements, frequently promoting its 1-800-PetMeds and PetMeds brands. The company was established in 1996 and is headquartered in Delray Beach, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

PetMed (PETS) Reports Q2 Loss, Lags Revenue Estimates
PetMed (PETS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.41 per share a year ago.

PetMed Express, Inc. (PETS) Q2 2027 Earnings Call Prepared Remarks Transcript
PetMed Express, Inc. (PETS) Q2 2027 Earnings Call Prepared Remarks Transcript

PetMedsยฎ Announces Second Quarter Financial Results
DELRAY BEACH, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2026.

PetMeds Announces Strategic Partnership with Pet Supermarket to Expand Pharmacy Offering Across Retail and Digital Channels
DELRAY BEACH, Fla., Nov. 09, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced a new partnership with Pet Supermarket to offer pet prescription med

PetMed Express, Inc. to Report Second Quarter Fiscal Year 2027 Financial Results on Tuesday, November 10, 2026
DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year

PetMeds Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DELRAY BEACH, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx (Nasdaq: PETS), today announced that PetMeds recently granted equity awards previously approved by i